The field of genetic testing for inherited cancer is rapidly evolving. Identification of *BRCA1* and *BRCA2* paved the way for personalized medicine and created a new paradigm for hereditary breast and ovarian cancer (HBOC) syndrome diagnosis and prevention ([@bibr28-1099800417750746]; [@bibr35-1099800417750746]). Likewise, discovery of the molecular basis of Lynch syndrome led to a clearer definition of the syndrome's clinical spectrum and improved our ability to identify individuals at high risk of hereditary colon and endometrial cancers ([@bibr31-1099800417750746]). Identification of mutation carriers is critical, as it enables the administration of interventions that are proven to confer significant survival benefits, particularly for highly penetrant genetic mutations ([@bibr25-1099800417750746]).

Beyond these two well-known syndromes, numerous other genes associated with hereditary cancer syndromes have been identified in recent years. Concurrently, advances in next-generation sequencing (NGS) technology have made it possible to test multiple genes simultaneously. Inherited cancer testing is now being offered by a variety of specialists in a multitude of clinical settings for both affected and unaffected individuals ([@bibr6-1099800417750746]).

Genetic counseling and testing is often performed by health-care providers with specialized training in clinical genetics. These providers include board-certified genetic counselors, board-certified clinical geneticists, and advanced practice genetic nurses who are certified by the American Nursing Credentialing Center based on minimum practice hours within the specialty and continuing education hours ([www.nursecredentialing.org](http://www.nursecredentialing.org)). However, because of their consistent and sustained interactions with patients, nurses of various backgrounds are well positioned to educate, support, and advocate for patients throughout the genetic testing process by effectively obtaining family histories, identifying test candidates, helping patients and families understand results, and incorporating genetic test results into ongoing care ([@bibr13-1099800417750746]). All registered nurses have received broad training in genetics, while master's-level nurses achieve a more rigorous set of genetic and genomic proficiencies ([www.ncsbn.org](http://www.ncsbn.org)), but given the rapid changes in this field, ongoing education is imperative. This article reviews how multigene testing is performed using NGS technology and highlights counseling considerations associated with multigene hereditary cancer testing.

Overview of Sequencing Technologies {#section1-1099800417750746}
===================================

NGS refers to a collection of technologies that allow for the parallel sequencing of millions of DNA fragments. With the previous standard, Sanger sequencing, one molecule is sequenced at a time ([@bibr87-1099800417750746]). Despite their stark differences in throughput, Sanger sequencing and NGS share a similar molecular foundation: Both utilize the cell's own DNA-copying process to elucidate the sequence of a targeted portion of the genome ([Figure 1](#fig1-1099800417750746){ref-type="fig"}). A single cycle of NGS involves (1) single-base extension (such that every piece of DNA is now fluorescent at its terminus with a color corresponding to the terminal base), (2) imaging of the fluorescence color at every position on the glass slide, and (3) recycling of the terminal bases such that they are no longer fluorescent and can undergo extension again. NGS sequencers can perform hundreds of such cycles, yielding millions of DNA-fragment sequences, each up to several hundred bases in length. Although at the molecular level NGS and Sanger technologies subtly differ, this difference makes NGS clinically groundbreaking. NGS throughput and quality has greatly decreased both the cost and time involved in sequencing, allowing patients access to testing for multiple genes at a fraction of the cost of traditional single-gene testing.

![Traditional Sanger sequencing compared with next-generation sequencing technology. In each method, dyed, unextendable bases are utilized to create a fluorescent signal that can be translated into a sequence of nucleotides. Subtle differences in the two methods lead to vast differences in throughput. This image was reproduced from figure 1 in [@bibr66-1099800417750746]. It is licensed under Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>).](10.1177_1099800417750746-fig1){#fig1-1099800417750746}

Depth of Coverage on NGS {#section2-1099800417750746}
------------------------

The goal of genetic testing is to resolve the sequence of a patient's genes such that any pathogenic mutations can be identified. Therefore, it is important to sequence molecules originating from each chromosome many times over to have confidence in the result. *Depth*, or *coverage*, refers to the number of sequenced fragments that are generated from a given site in the genome or simply the number of times a certain base was sequenced. In general, as depth increases, so does the confidence that the identified mutation is real. Most commercial laboratories establish a minimum depth between 20× and 50× for targeted inherited cancer panels, which means that at each genomic position, a base is read at least 20--50 times ([@bibr15-1099800417750746]; [@bibr48-1099800417750746]; [@bibr58-1099800417750746]; [@bibr104-1099800417750746]).

Variant Identification and Classification {#section3-1099800417750746}
-----------------------------------------

Pathogenic mutations can occur when nucleotides, varying from a single base to thousands, are altered, inserted, or deleted ([Figure 2](#fig2-1099800417750746){ref-type="fig"}). Any sequencing method used for clinical testing must be able to identify this wide variety of mutation types that can lead to human disease. Once a genetic alteration is identified, a laboratory must then determine the biological significance of that alteration through the process of variant curation. The American College of Medical Genetics and Genomics (ACMG) sets standards for classifying genetic alterations into five categories: pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. These classifications are based on multiple lines of evidence including public and private databases as well as population, computational, functional, segregation, de novo, and allelic data ([@bibr80-1099800417750746]). Because of the difficulty of developing rigid guidelines that encompass all nuances of genetic variation, there is the potential for differences in classifications between laboratories, and based on analysis of public database submissions, such differences in classification have occurred ([@bibr39-1099800417750746]). However, authors report overall high interlaboratory concordance for hereditary cancer results when the clinical actionability of a variant and quality of a database submission is considered ([@bibr59-1099800417750746]). Concordance will continue to increase with ongoing data sharing efforts among researchers and commercial laboratories. Genomic data sharing, through contribution to public databases such as ClinVar ([www.ncbi.nlm.nih.gov/clinvar](http://www.ncbi.nlm.nih.gov/clinvar)), is supported by ACMG as a crucial practice in improving genomic health care ([@bibr1-1099800417750746]).

![Next-generation sequencing reads aligned to a reference genome demonstrate two mutation types: a single-nucleotide polymorphism where a guanine has replaced a thymine and, further downstream, a deletion of an adenine. Depth of coverage of 3×, 5×, and 8× indicates the number of reads at each position. This image was adapted from figure 2 in [@bibr66-1099800417750746]. It is licensed under Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>). Modifications were made to include only a portion of the original image.](10.1177_1099800417750746-fig2){#fig2-1099800417750746}

Confirmation of NGS Findings {#section4-1099800417750746}
----------------------------

In its early usage, NGS was limited by low depth of coverage and error rates that were unsuitable for routine clinical testing. Confirmation of results through traditional methods, such as Sanger sequencing, was common laboratory practice. Although NGS can now be optimized for low error rates and high depth of coverage, some laboratories still rely on orthogonal confirmation of positive findings ([@bibr15-1099800417750746]; [@bibr48-1099800417750746]; [@bibr58-1099800417750746]; [@bibr104-1099800417750746]). In a recent study, authors analyzed data from 20,000 clinical samples tested at one commercial laboratory and claimed the necessity of utilizing Sanger sequencing to confirm variants detected by NGS ([@bibr65-1099800417750746]). However, many other reports have demonstrated that NGS alone produces results with high sensitivity and specificity and that the need for orthogonal confirmation is dependent on the specific NGS assay and is not a general limitation of all NGS protocols ([@bibr5-1099800417750746]; [@bibr58-1099800417750746]; [@bibr104-1099800417750746]). Nonetheless, the purpose of orthogonal confirmation is to reduce false positives. It is important, therefore, for laboratories to establish a protocol for addressing the potential for such results, especially in difficult-to-sequence regions of the genome, and to demonstrate the efficacy of these protocols in published validation studies ([@bibr65-1099800417750746]).

Assessing Quality of NGS Testing {#section5-1099800417750746}
--------------------------------

The Center for Medicare and Medicaid Services Clinical Laboratory Improvement Amendment program stipulates standards for analytic validity of NGS assays but does not address the accuracy of individual aspects of these methods such as depth of coverage, bioinformatics for variant calling, results interpretation, or reporting ([@bibr83-1099800417750746]). Most commercially available assays report greater than 99% sensitivity, specificity, and accuracy but use varying methods to achieve this standard ([@bibr15-1099800417750746]; [@bibr48-1099800417750746]; [@bibr58-1099800417750746]; [@bibr104-1099800417750746]). Experts call for clinicians to carefully select a laboratory for testing but give little guidance for how to assess laboratory quality ([@bibr33-1099800417750746]). Laboratories can demonstrate their test performance through a published validation study. Analytical sensitivity, analytic specificity, repeatability, and reproducibility are all characteristics that a test validation should establish ([@bibr78-1099800417750746]).

Overview of Multigene Testing {#section6-1099800417750746}
=============================

Multigene testing for cancer susceptibility became commercially available in 2012 ([@bibr21-1099800417750746]). Although many laboratories now offer these tests using similar NGS technologies, panel design (e.g., panel size, how genes are selected for inclusion, design of syndrome-specific panels) can vary greatly between laboratories ([@bibr19-1099800417750746]; [@bibr24-1099800417750746]; [@bibr41-1099800417750746]; Slavin et al., 2015). The National Comprehensive Cancer Network (NCCN) recommends consideration of multigene testing when a patient's personal and/or family history is suggestive of an inherited cancer syndrome that could be caused by more than one gene or when an individual has tested negative for a single syndrome, but their personal and/or family history remains suggestive of an inherited cause ([@bibr67-1099800417750746]). However, due to decreasing cost and turnaround time, multigene panels are more often being used as a first-line test for any patient suspected to have an inherited cancer syndrome.

Although *BRCA1* and *BRCA2* are the most recognized hereditary cancer genes, mutations in these genes only account for 50% of all hereditary breast cancer ([@bibr49-1099800417750746]). Multiple studies have demonstrated that multigene testing identifies more individuals with hereditary breast cancer than testing for *BRCA1/2* alone. For individuals suspected of having hereditary breast cancer who previously tested negative for *BRCA1/2*, testing for additional genes results in a positive result in 2.9--11.4% of cases ([@bibr23-1099800417750746]; [@bibr49-1099800417750746]; [@bibr53-1099800417750746]; [@bibr63-1099800417750746]; [@bibr99-1099800417750746]; [@bibr101-1099800417750746]; [@bibr106-1099800417750746]).

Another common indication for hereditary cancer testing is a personal or family history of colon cancer. In the first large clinical series of patients tested for inherited colorectal cancer (CRC) with multigene panel testing, 10% of high-risk patients tested positive for a mutation in 1 of the 14 genes associated with nine CRC syndromes; the majority of these results were expected to change clinical management ([@bibr19-1099800417750746]). In a larger, subsequent series, 1,260 patients with suspected Lynch syndrome were tested using a 25-gene panel, and 185 (14.6%) were found to have a pathogenic mutation; 38% of mutations were in non-Lynch syndrome genes ([@bibr107-1099800417750746]).

Overlapping phenotypes and complex guidelines may lead to patients being missed with the traditional single-gene testing approach. In a study of 9,000 individuals referred for hereditary cancer testing, 30% of patients tested for Lynch syndrome also met criteria for HBOC testing, and inversely, 7% of patients sent for HBOC testing also met criteria for Lynch syndrome testing ([@bibr85-1099800417750746]). Multigene tests may offer a simplified and efficient option for clinicians needing to select appropriate genes for a given patient. A growing body of evidence also suggests that adhering to a guidelines-based approach, testing solely for a gene or syndrome for which a patient meets criteria, can lead to missed mutations. In a study of 475 patients referred for genetic counseling and testing at an academic center, 15.6% were positive for a mutation identified through multigene testing ([@bibr81-1099800417750746]). Based on provider-recorded differential diagnoses, the authors determined that nearly half of these mutations (47.3%) would have been missed with a single-gene, stepwise approach. The potential missed mutations included those in high-penetrance genes with atypical presentations as well as those in moderate-penetrance genes where the phenotype is less well defined. Other studies have reported similar findings, with 6.6--17% of individuals referred for multigene testing being found to carry a pathogenic mutation in at least one gene ([@bibr54-1099800417750746]; [@bibr90-1099800417750746]; [@bibr93-1099800417750746]; [@bibr96-1099800417750746]).

Despite the advantages of multigene testing, some argue that new DNA testing technology is outpacing evidence for clinical utility and consideration of proper implementation. Multigene tests may include genes with ill-defined lifetime cancer risks, unclear clinical management guidance, and increased rates of results with uncertain significance ([@bibr4-1099800417750746]; [@bibr24-1099800417750746]; [@bibr83-1099800417750746]). Further carefully designed studies with large sample sizes are needed to demonstrate the clinical validity and clinical utility of multigene testing ([@bibr29-1099800417750746]).

Categories of Risk {#section7-1099800417750746}
==================

Cancer predisposition genes included on multigene tests can be grouped into three categories of disease penetrance: high, moderate, and low. There is also a growing category of genes that have been associated with risk of cancer, but the magnitude of this risk is unknown due to limited available data.

The likelihoods of the development of cancer due to genetic mutations can be discussed in terms of relative risk (RR) or lifetime risk (LTR). RR, also called a risk ratio, is the likelihood of an event's occurrence in one group compared with that in another group. For example, the RR of developing breast cancer for a *PALB2* mutation carrier is 5.3 ([@bibr29-1099800417750746]), meaning that a woman with a pathogenic *PALB2* mutation is 5.3 times more likely to develop breast cancer compared to a woman in the general population. Absolute risk refers to the probability of an event happening over a defined period of time, for example, the likelihood of breast cancer manifestation in the next 5 years or over a lifetime.

Calculations of lifetime cancer risks are influenced by risk factors, such as family history, environmental exposures, or hormonal factors, and can overestimate risk of genes where risk ratio may decrease as carriers age ([@bibr29-1099800417750746]). However, absolute risks may be more relevant in clinical practice since guidelines cite 5-year risk and LTR in recommendations for interventions such as chemoprevention and magnetic resonance imaging (MRI) screening for breast cancer ([@bibr88-1099800417750746]). [Table 1](#table1-1099800417750746){ref-type="table"} displays a list of genes commonly found on multigene cancer tests and respective lifetime cancer risks. It is important to note that individuals who test negative for a genetic mutation may still have an elevated risk of cancer based on personal or family history. Multiple risk models are available to calculate breast cancer risk in families who do not harbor an identifiable mutation (e.g., Claus model, [@bibr16-1099800417750746], Tyrer--Cuzick model). However, current risk models have limitations, and it is important to understand the specific limitations of each model when calculating risk of a given patient ([@bibr2-1099800417750746]).

###### 

Genes Commonly Included on Multigene Hereditary Cancer Tests and Their Associated LTRs of Cancer.

![](10.1177_1099800417750746-table1)

  Gene                             LTR of Cancer      Increased Risk of Other Cancers   Citation                                                                                                             
  -------------------------------- ------------------ --------------------------------- ------------------------- ------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------
  **High risk**                                                                                                                                                                                              
  * APC*                                                                                Up to 100%                Medulloblastoma, papillary thyroid, and hepatoblastoma                                     [@bibr9-1099800417750746]; [@bibr12-1099800417750746]
  * BMPR1A*                                                                             39--68%                   Gastric                                                                                    [@bibr44-1099800417750746]; [@bibr74-1099800417750746]
  * BRCA1*                         46--87%            39--63%                                                     Prostate, pancreatic, and male breast cancer                                               [@bibr28-1099800417750746]; [@bibr35-1099800417750746]; [@bibr46-1099800417750746]; [@bibr55-1099800417750746]; [@bibr62-1099800417750746]
  * BRCA2*                         38--84%            17--27%                                                     Prostate, pancreatic, and male breast                                                      [@bibr28-1099800417750746]; [@bibr35-1099800417750746]; [@bibr46-1099800417750746]; [@bibr52-1099800417750746]; Van [@bibr103-1099800417750746]
  * CDH1*                          39--52%                                                                        Diffuse gastric                                                                            [@bibr28-1099800417750746]; [@bibr40-1099800417750746]; [@bibr72-1099800417750746]
  * EPCAM*                                                                              40--75%                   Endometrial, stomach, hepatobiliary tract, small bowel, urinary tract, brain, and others   [@bibr50-1099800417750746]); [@bibr56-1099800417750746]; [@bibr102-1099800417750746]
  * MLH1*                                             4--24%                            52--82%                   Endometrial, stomach, hepatobiliary tract, small bowel, urinary tract, brain, and others   [@bibr10-1099800417750746]; [@bibr19-1099800417750746]
  * MSH2*                                             4--24%                            52--82%                   Endometrial, stomach, hepatobiliary tract, small bowel, urinary tract, brain, and others   [@bibr10-1099800417750746]; [@bibr19-1099800417750746]
  * MSH6*                                             1--11%                            10--22%                   Endometrial, stomach, urinary tract                                                        [@bibr10-1099800417750746]; [@bibr19-1099800417750746]
  * MUTYH* (biallelic)             May be increased   May be increased                  43--100%                  Possibly increased for small bowel and other                                               [@bibr32-1099800417750746]; [@bibr61-1099800417750746]; [@bibr86-1099800417750746]; [@bibr92-1099800417750746]
  * PALB2*                         17--58%                                                                        Pancreatic and male breast                                                                 [@bibr3-1099800417750746]; [@bibr14-1099800417750746]; [@bibr76-1099800417750746]
  * PMS2*                                                                               10--22%                   Endometrial and small increased risk of other cancers---not well defined                   [@bibr19-1099800417750746]; [@bibr91-1099800417750746]; [@bibr98-1099800417750746]
  * POLE*                                                                               64%^a^                    Duodenal adenomas and brain                                                                [@bibr7-1099800417750746]; [@bibr94-1099800417750746]
  * POLD1*                         14.3%^a^                                             59%^a^                    Endometrial and brain                                                                      [@bibr7-1099800417750746]
  * PTEN*                          75--85%                                              9--18%                    Thyroid, endometrial, and renal                                                            [@bibr11-1099800417750746]; [@bibr19-1099800417750746]; [@bibr73-1099800417750746]; [@bibr97-1099800417750746]
  * RAD51C*                                           9%                                                                                                                                                     [@bibr60-1099800417750746]; [@bibr70-1099800417750746]
  * RAD51D*                        may be increased   10%                                                                                                                                                    [@bibr60-1099800417750746]; [@bibr70-1099800417750746]
  * SMAD4*                                                                              38--69%                                                                                                              [@bibr44-1099800417750746]; [@bibr74-1099800417750746]
  * STK11*                         30--80%            18--21%                           30--39%                   Stomach and pancreatic                                                                     [@bibr19-1099800417750746]; [@bibr38-1099800417750746]; [@bibr43-1099800417750746]; [@bibr57-1099800417750746]
  * TP53*                          80--100%           20%                               May be increased          Sarcoma, brain, and adrenocortical carcinoma (overall cancer risk \> 90%)                  [@bibr51-1099800417750746]; [@bibr69-1099800417750746]
  **Moderate risk/limited data**                                                                                                                                                                             
  * ATM*                           7--52%^b^                                                                      Some evidence for increased risk of pancreatic and other cancers                           [@bibr8-1099800417750746]; [@bibr17-1099800417750746]; [@bibr28-1099800417750746]; [@bibr79-1099800417750746]
  * BRIP1*                                            5.8%                                                                                                                                                   [@bibr28-1099800417750746]; [@bibr75-1099800417750746]; [@bibr77-1099800417750746]; [@bibr89-1099800417750746]
  * CHEK2*                         26--56%^c^         May be increased                                                                                                                                       [@bibr28-1099800417750746]; [@bibr100-1099800417750746]; [@bibr105-1099800417750746]
  * GREM1*                                                                              Increased, limited data                                                                                              [@bibr47-1099800417750746]; [@bibr74-1099800417750746]; [@bibr84-1099800417750746]
  * NBN*                           Up to 30%^d^                                                                   Prostate                                                                                   [@bibr95-1099800417750746]; [@bibr20-1099800417750746]; [@bibr108-1099800417750746]

*Note.* LTR = lifetime risk.

^a^Risk estimates based on limited data. ^b^Highest risk based on the mutation 7271T \> G. ^c^Most data utilized for estimating risks based on common 1100delC mutation. ^d^Most data utilized for estimating risks based on Slavic mutation 657del5.

Although risk categories are somewhat arbitrary, high penetrance describes genes conferring an RR greater than 4 times the risk of the general population ([@bibr29-1099800417750746]). Examples include *BRCA1* (RR 11.4, LTR 46--87%) and *PALB2* (RR 5.3, LTR 17--58%). Moderate-penetrance genes confer an RR 2--4 times the general population risk. Examples include *CHEK2* (RR 3.0, LTR 26--56%) and *ATM* (RR 2.8, 7--52%; [@bibr29-1099800417750746]). Genes that confer cancer risks less than 2 times the general population risk may be referred to as low-penetrance genes or risk alleles. Most commercially available multigene tests include only moderate- and high-penetrance genes. However, not all mutations within a moderate- or high-penetrance gene confer equal risks of cancer. For example, a common mutation in *CHEK2*, 1100delC, confers an approximate 3-fold RR of breast cancer ([@bibr105-1099800417750746]), but another well-documented mutation in the same gene, I157T, is associated with only a 1.58-fold RR of breast cancer ([@bibr42-1099800417750746]).

Although it is controversial, many commercially available inherited cancer panels also include genes with limited or conflicting evidence for association with cancer risk and the magnitude of that risk. For example, the Mre11-Rad50-Nbs1 (MRN) complex, which includes the genes *MRE11A*, *RAD50*, and *NBN*, is involved in double-strand break repairs. Data have shown that mutations in genes that make up the MRN complex confer either a moderately increased risk of breast cancer ([@bibr22-1099800417750746]) or no increased risk ([@bibr18-1099800417750746]). All three genes are included on many multigene cancer tests, but currently, only the *NBN* gene has corresponding consensus guidelines for management ([@bibr67-1099800417750746]). More studies are needed to establish the appropriate evidence threshold for inclusion of a specific gene in clinical testing.

Counseling Considerations {#section8-1099800417750746}
=========================

Although NGS technology has brought significant benefit to clinical genetics, genetic counseling in the era of panel testing can be more complex than for single-gene testing. These complexities come in the form of new challenges but more commonly stem from traditional challenges in genetic counseling that are amplified by testing for many genes simultaneously. It is important that all clinicians who order hereditary cancer panels are equipped with the knowledge to navigate these complexities, stay up to date with rapidly changing guidelines, and maintain a network of genetics professionals to refer patients to when required.

Pretest Education and Informed Consent Considerations {#section9-1099800417750746}
-----------------------------------------------------

The informed consent process for genetic testing, whether for single-gene testing or multigene testing, requires the same basic elements: description of its purpose, general information about the genes being tested, potential test results, accuracy, financial considerations, potential for genetic discrimination, confidentiality, actionability of test results for patient and family members, psychological implications of a test result, and alternatives to genetic testing ([@bibr82-1099800417750746]). Health-care providers or genetics professionals may want to consider modifying this traditional approach to informed consent in the case of multigene testing to ensure that patients have a high-level understanding of the genes for which they are being tested as well as a heightened awareness of the potential to find an unexpected, uncertain, or unclear result ([@bibr83-1099800417750746]).

Pretest counseling for single-gene or single-syndrome testing historically included a comprehensive discussion of the hereditary cancer gene(s) for which the patient is being tested. For example, a candidate for Lynch syndrome testing may have formerly received a detailed explanation of each of the genes associated with Lynch syndrome, the cancer risks associated with a positive result in each gene, as well as the medical management guidelines for carriers. In order to remain effective, pretest counseling for multigene tests requires modification since it is not feasible to have a comprehensive discussion about each gene on a large panel ([@bibr83-1099800417750746]). Instead, bucketing genes into categories of risk can provide the necessary education without information overload ([Table 2](#table2-1099800417750746){ref-type="table"}; [@bibr33-1099800417750746]).

###### 

Examples of Risk Categories to Aid in Simplification of Pretest Counseling in the Case of Multigene Testing.

![](10.1177_1099800417750746-table2)

  Patient Concern                   High-Penetrance Genes                                                                               Moderate-Penetrance Genes                                                                                                                                  Limited Data/Low-Risk Genes
  --------------------------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Cancer risk                       High cancer risks, likely explains cancer in family                                                 Moderate cancer risks, may explain cancer in family                                                                                                        Unknown cancer risk, may explain cancer in the family
  Medical-management options        Many options, which may include increased screening, preventative surgery, and chemoprevention^a^   Options generally involve increased screening beginning at younger ages                                                                                    Established guidelines not yet available; clinician will make recommendations based on current data and the patient's personal and family medical history
  Implications for family members   Recommend testing to all blood relatives. Negative results are considered "true negative" results   Family members should consider genetic testing; family members with negative results may still have increased risk of cancer based on the family history   Unknown implications for family members

^a^It is important to discuss limitations in cancer screening and prevention. It is not possible to effectively screen for all cancer risks conferred by a high-penetrance gene. For example, *TP53* mutations cause risk of many cancer types, and screening options are of unknown efficacy.

Discussing the potential for uncertain findings has been an integral part of pretest education and informed consent since the beginning of clinical testing for hereditary cancer ([@bibr71-1099800417750746]). In 2002, the variant of uncertain significance (VUS) rate for *BRCA1* and *BRCA2* alone was as high as 12.8%, but it decreased to 2.1% as knowledge accumulated on the effects of specific genetic alterations ([@bibr30-1099800417750746]). The likelihood for a VUS to be identified on a multigene cancer test varies based on many factors including the number of genes tested, the quantity of the region of interest being sequenced (i.e., how much of the introns, or noncoding region, is included), and the ethnic diversity of the population being tested, but it can range from 19.7% to 42% ([@bibr90-1099800417750746]; [@bibr93-1099800417750746]). Preparing patients for the possibility of an uncertain result prior to testing may help to normalize this result and alleviate patient anxiety when a VUS is identified. It is important to recognize that, as labs and clinicians collaborate and participate in broad data sharing practices, VUS rates will continue to decrease, which will benefit patient care in genetics ([@bibr1-1099800417750746]).

The potential for genetic discrimination is another aspect of pretest counseling that is not new but has become a more important issue as more individuals, particularly those who have not had cancer, gain access to genetic testing services. Multigene tests are more likely to return a positive result than single-gene tests and therefore may introduce more potential for genetic discrimination. The Genetic Information Nondiscrimination Act (GINA) is a federal law passed in 2008 that provides protections against genetic discrimination in health insurance and employment. The law disallows use of genetic information by a health insurer to make determinations about premiums and states that health insurers may not require subscribers undergo genetic testing. The law does have some limitations in its protections. For example, GINA does not apply to life insurance, long-term care insurance, or disability insurance. It also does not apply to employers with fewer than 15 employees, members of the U.S. military, veterans accessing health care through the U.S. Department of Veterans Affairs, or federal employees enrolled in the Federal Employees Health Benefits program ([@bibr37-1099800417750746]). The Affordable Care Act, the Health Insurance Portability and Accountability Act, and numerous state laws provide additional protections against genetic discrimination in health insurance ([@bibr68-1099800417750746]). It is important to discuss the protections, and the limitations in protections, with patients prior to their undergoing genetic testing.

Posttest Counseling Considerations {#section10-1099800417750746}
----------------------------------

Posttest, a discussion with a patient on results includes sensitivity, specificity, and limitations of the test; the patient's cancer risks based on the result; medical management recommendations; and implications for family members. Referral to other health-care providers as well as assessment of psychological impacts and provision of emotional support can also be vital parts of this process ([@bibr82-1099800417750746]). Similar to pretest counseling, posttest counseling with multigene testing is at the core very similar to that for single-gene testing, but it does pose a few unique challenges.

### Identifying unexpected results {#section11-1099800417750746}

While rare, "unexpected findings" occur when individuals test positive for a mutation in a gene that is not associated with their personal or family history. For example, pathogenic mutations in *CDH1* are associated with increased risk of developing diffuse gastric cancer and lobular breast cancer ([@bibr72-1099800417750746]), and experts recommend genetic testing in families that have multiple cases of diffuse gastric cancer, diffuse gastric cancer diagnosed in an individual younger than 40 years of age, or individuals with a personal history of both diffuse gastric cancer and lobular breast cancer ([@bibr34-1099800417750746]). However, since pan-cancer multigene tests have become available, there have been multiple case reports of patients found to carry pathogenic mutations in *CDH1* with no reported personal or family history of diffuse gastric cancer ([@bibr45-1099800417750746]). Risks of cancer and guidelines for management of individuals with *CDH1* mutations were developed based on data from families with significant histories of gastric cancer. It is unclear whether *CDH1* carriers without a significant history have the same risks and should be managed in the same way. The conservative approach, guided by studies of *BRCA* mutations identified in low-risk families ([@bibr36-1099800417750746]), assumes the same level of cancer risk of any *CDH1* mutation carrier, but more studies are needed to better understand the appropriate management of these individuals and individuals in other families with unexpected findings from multigene testing.

### Pathogenic mutations in multiple genes {#section12-1099800417750746}

Multigene testing introduces the possibility of identifying pathogenic mutations in multiple genes in one individual. In a cohort of more than 2,000 patients, investigators found that 2.9% carried two pathogenic mutations ([@bibr54-1099800417750746]). Although this finding suggests that individuals with known familial mutations identified by single-gene testing may still benefit from a multigene test, limited data exist to guide the management of individuals with more than one inherited cancer predisposition syndrome. Large, prospective studies are needed to define cancer risks in individuals who carry mutations in two or more genes, so that appropriate management recommendations can be developed. In the meantime, management of both syndromes according to their independent guidelines is a reasonable approach.

### Management and moderate-penetrance genes {#section13-1099800417750746}

Many moderate-penetrance genes, like *CHEK2*, were discovered long before clinical testing of these genes was common ([@bibr64-1099800417750746]). With single-gene testing, limited value was outweighed by incremental cost. NGS technology allows these genes to be included in multigene tests with little additional cost. While the addition of moderate-penetrance genes to multigene cancer tests preceded the existence of clinical management guidelines, experts have now established a framework for counseling carriers about their risk ([@bibr67-1099800417750746]; [@bibr100-1099800417750746]). However, while guidelines for managing carriers develop, establishment of cancer risks of family members remains challenging. Prior studies support that when a family member tests negative for a known familial high-penetrance mutation, like a *BRCA1* or *BRCA2* mutation, they are considered to be a "true negative" and their risk of cancer approaches that of the general population regardless of family history ([@bibr26-1099800417750746]). It may not be appropriate to apply this same approach to moderate-penetrance genes. Moderate-penetrance genes, like *ATM*, may not account for all cancer risk in a family, as gene/gene and gene/environment interactions may also contribute ([@bibr67-1099800417750746]). For this reason, family members who test negative for a familial moderate-penetrance mutation may still have an increased risk of cancer based on their personal and family history and should be counseled accordingly ([@bibr100-1099800417750746]).

Inclusion of genes with limited or conflicting evidence of cancer risk can pose additional challenges to multigene testing. Consensus guidelines state that genetic testing is most appropriate when results of testing will have a direct impact on the medical management of the patient or their family members ([@bibr67-1099800417750746]). Therefore, genetic testing with a guidelines-based panel is a reasonable approach. Genes that have uncertain clinical utility should be included in clinical testing with caution, and the involvement of a provider with expertise in cancer genetics and risk assessment is important in these circumstances ([@bibr83-1099800417750746]).

### Counseling about variants of uncertain significance {#section14-1099800417750746}

Rates for VUS identified on multigene hereditary cancer panels range from 19.7% to 42% ([@bibr90-1099800417750746]; [@bibr93-1099800417750746]), with one report of a VUS rate of 88% for a 42-gene panel ([@bibr53-1099800417750746]). Although multigene panels have higher VUS rates than traditional single-gene testing, posttest counseling and management of patients with VUS identified with either technology are similar. Because most VUS results that are reclassified are found to be benign, VUS results should not be used to alter clinical management ([@bibr27-1099800417750746]). Instead, a patient with a VUS should receive individualized recommendations based on their personal and family history ([@bibr67-1099800417750746]). Providers can encourage patients to enroll in research studies that are working collaboratively toward improved interpretation of genetic variants such as ClinGen ([www.clinicalgenome.org](http://www.clinicalgenome.org)), PROMPT ([www.promptstudy.info](http://www.promptstudy.info)), ENIGMA ([www.enigmaconsortium.org](http://www.enigmaconsortium.org)), or InSIGHT ([www.insight-group.org](http://www.insight-group.org)).

### Counseling for reproductive risks {#section15-1099800417750746}

Discussion of reproductive risks with carriers is another complex issue that is not unique to, but may be increasing in frequency because of, multigene testing. Many genes cause increased risk of cancer when carriers inherit one mutation from one parent but lead to a different genetic syndrome when they inherit two mutations, one from each parent. Reproductive risks should be discussed with carriers of mutations in the genes in [Table 3](#table3-1099800417750746){ref-type="table"}, and carriers should be made aware of the availability of partner testing to clarify the risk of conceiving a child with a clinically distinct genetic condition.

###### 

Genes Commonly Found on Multigene Cancer Panels That Are Also Associated With Other Phenotypes in Individuals With Two Mutations.

![](10.1177_1099800417750746-table3)

  Gene(s)       Heterozygous                                    Homozygous or Compound Heterozygous
  ------------- ----------------------------------------------- ----------------------------------------------------
  *ATM*         *ATM*-associated hereditary cancer              Ataxia telangiectasia
  *BRCA2*       Hereditary breast and ovarian cancer syndrome   Fanconi anemia (complementation group D1---FANCd1)
  *BRIP1*       *BRIP1*-associated hereditary cancer            Fanconi anemia (complementation group J---FANCJ)
  *MMR* genes   Lynch syndrome                                  Constitutional mismatch repair deficiency
  *NBN*         *NBN*-associated hereditary breast cancer       Nijmegen breakage syndrome
  *PALB2*       *PALB2*-associated hereditary cancer            Fanconi anemia (complementation group N---FANCN)
  *RAD51C*      *RAD51C*-associated hereditary cancer           Fanconi anemia (complementation group O---FANCO)
  *RAD51D*      *RAD51D*-associated hereditary cancer           Fanconi anemia^a^

*Note.* Counseling for these syndromes should include discussion about reproductive risks. *MMR* = mismatch repair.

^a^ *RAD51D* is involved in the Fanconi anemia pathway, but there are no reported cases of Fanconi anemia with mutations in *RAD51D*.

Ongoing Communication {#section16-1099800417750746}
---------------------

Providers ordering hereditary cancer testing of any type must be aware of changing guidelines, and this imperative is especially true for multigene panel testing. Patients' family histories, guidelines for testing criteria, interpretation of variants, and management recommendations for mutation carriers are all evolving. Clinicians must establish a protocol to ensure that patients have access to current recommendations surrounding their hereditary cancer risk.

Conclusions {#section17-1099800417750746}
===========

Multigene testing allows for increased detection of hereditary cancer syndromes by utilizing the benefits of high-throughput NGS. Genetic counseling complexities may arise on a more frequent basis with panel testing; however, these challenges are not novel to counseling for inherited cancer. Nurses of all levels and specialties can play an integral role in identifying, testing, and managing patients with inherited risk of cancer. All health-care professionals who offer inherited cancer testing must engage in ongoing education as the field is continuously evolving as new data become available. Future research opportunities are many in this field and include analysis of clinical utility for moderate-penetrance genes, delineation of cancer risks and management for individuals positive for mutations in multiple genes, development of robust standards to assess lab quality, and data collection to further refine cancer risks conferred by more newly described genes, especially in diverse populations. While these data will undoubtedly improve upon the usefulness of multigene testing, the current landscape represents an opportunity to expand the number of individuals who can receive timely and appropriate clinical guidance.

Supplementary Material
======================

###### Supplementary material

The authors would like to acknowledge Dale Muzzey, PhD, who provided guidance for the next-generation sequencing technologies portion of this review.

**Author Contribution:** K. Price contributed to conception, design, data acquisition, data analysis, and interpretation; drafted the manuscript; critically revised the manuscript; gave final approval; and agrees to be held accountable for all aspects of work, ensuring integrity and accuracy. A. Svenson contributed to conception, design, data acquisition, data analysis, and interpretation; drafted the manuscript; critically revised the manuscript; gave final approval; and agrees to be held accountable for all aspects of work, ensuring integrity and accuracy. E. King contributed to design, critically revised the manuscript, gave final approval, and agrees to be held accountable for all aspects of work, ensuring integrity and accuracy. K. Ready contributed to design, critically revised the manuscript, gave final approval, and agrees to be held accountable for all aspects of work, ensuring integrity and accuracy. G. Lazarin contributed to conception and design, critically revised the manuscript, gave final approval, and agrees to be held accountable for all aspects of work, ensuring integrity and accuracy.

**Declaration of Conflicting Interests:** The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All authors, with the exception of Ms. King, are employees of Counsyl, a laboratory providing inherited cancer screening.

**Funding:** The author(s) received the following financial support for the research, authorship, and/or publication of this article: This study was funded by Counsyl, a laboratory providing inherited cancer screening.

**ORCID iD:** Gabriel A. Lazarin, MS, CGC ![](10.1177_1099800417750746-img1.jpg) <http://orcid.org/0000-0001-5061-8595>

**Supplemental Material:** Supplementary material is available for this article online.
